DeCure's autonomous Rare AI scientist is researching a drug-repurposing hypothesis for amblyopia — screening already-approved drugs against its 22-gene Open Targets disease module to publish open-access research. Research is fast; the path to publication is funded in milestone stages.
Disease moduleAmblyopia maps to a 22-gene Open Targets module — the target space DeCure's AI scientist screens approved drugs against.
DeCure.ai methodSignature reversal (LINCS) plus network proximity (STRING) rank already-approved drugs likely to perturb this module — the same engine that produces DeCure.ai's repurposing hypotheses.
Repurposing thesisScreening approved medicines against this disease module, then publishing the evidence for the strongest candidate. Known pharmacology and human exposure data make the first question sharper — they do not establish safety or efficacy in a new indication.
Research record
01
ResearchComing soon
Candidate research + dossier — target rationale, drug-repurposing thesis and evidence pack.proof: Published dossier + on-chain hash
02
ValidationComing soon
In-vitro biological validation at a contract research org (CRO).proof: CRO contract + in-vitro report
03
Peer review & paperComing soon
Peer-reviewed paper published open-access (preprint + journal).proof: DOI + open-access link + on-chain hash
Current lead
No approved-drug candidate for amblyopia is corroborated in the literature DeepSearch retrieved. Some conditions are managed with non-pharmacological care — a device, surgery or physical therapy — rather than a medicine; that may be the case here, or the literature we found may simply be too sparse yet to support a drug-repurposing angle.
Molecular view
dopa decarboxylase (DDC) — DDC is one of the genes genetically linked to this disease in Open Targets — shown as context, not as a drug target we're pursuing: no approved-drug candidate for this disease is yet corroborated in the literature we found.
Loading structure…
helix sheet plpdrag to rotate · scroll to zoom
RCSB Protein Data Bank · entry 8OR9 · 1.9 Å · ligand PYRIDOXAL-5'-PHOSPHATE (PLP). Experimental structure, not a prediction.
What the evidence adds up to
In a 2011 study of 43 amblyopic patients with strabismus, anisometropia, or both, the degree of suppression measured by a dichoptic motion threshold technique correlated directly with the degree of amblyopia: stronger suppression was associated with a greater difference in interocular acuity and poorer stereoacuity. Suppression was not related to the type or angle of strabismus or to previous treatment history. The authors suggested suppression may have a primary role in the amblyopia syndrome, with implications for treatment.
A 2004 review noted that atropine had been found effective for amblyopia and that less intense patching regimens were also effective. A 1981 review mentioned anti-inhibitory pharmacologic agents and the CAM stimulator among specialised techniques. A 2008 review discussed dopaminergic agents and citicoline, claiming evidence of improvement in visual function from medical treatment alone or with part-time occlusion, and stated that medical treatment could be usefully included in therapy, particularly in difficult cases. The same review noted that animal data on substances capable of delaying plasticity in adults might be transferred to humans.
A 2016 update stated that new evidence from animal models and clinical trials had challenged the classical concept that amblyopia becomes untreatable after the end of the sensitive period, because of insufficient plasticity in the adult brain. It concluded that new treatments for children and adults are desirable but that further studies are needed before such therapies are widely accepted into clinical practice. A 2018 review summarised molecular biological mechanisms including visual neurotransmitters, cell factors, genes, proteins, and regulatory kinases, but provided no clinical data.
No randomised controlled trial has yet demonstrated that any pharmacological agent, including citicoline or dopaminergic drugs, produces sustained, clinically meaningful visual improvement in amblyopia that matches or exceeds standard occlusion or atropine. The molecular mechanisms described in 2018 have not been translated into a tested therapy. What is still missing are adequately powered, masked trials that compare medical treatments against established therapies in both children and adults, with long-term follow-up for durability and safety, and patient stratification by amblyopia subtype and age.
Evidence
Retrieved by DeepSearch across 234,678,978 indexed works and resolved on OpenAlex — ranked by citations, including the results that did not work.
AbstractPURPOSE: This study had three main goals: to assess the degree of suppression in patients with strabismic, anisometropic, and mixed amblyopia; to establish the relationship between suppression and the degree of amblyopia; and to compare the degree of suppression across the clinical subgroups within the sample. METHODS: Using both standard measures of suppression (Bagolini lenses and neutral density [ND] filters, Worth 4-Dot test) and a new approach involving the measurement of dichoptic motion thresholds under conditions of variable interocular contrast, the degree of suppression in 43 amblyopic patients with strabismus, anisometropia, or a combination of both was quantified. RESULTS: There was good agreement between the quantitative measures of suppression made with the new dichoptic motion threshold technique and measurements made with standard clinical techniques (Bagolini lenses and ND filters, Worth 4-Dot test). The degree of suppression was found to correlate directly with the degree of amblyopia within our clinical sample, whereby stronger suppression was associated with a greater difference in interocular acuity and poorer stereoacuity. Suppression was not related to the type or angle of strabismus when this was present or the previous treatment history. CONCLUSIONS: These results suggest that suppression may have a primary role in the amblyopia syndrome and therefore have implications for the treatment of amblyopia.
Current Opinion in Ophthalmology · 2016 · 26 citations
Amblyopia update
AbstractPURPOSE OF REVIEW: This review article is an update on the current treatments for amblyopia. In particular, the authors focus on the concepts of brain plasticity and their implications for novel treatment strategies for both children and adults affected by amblyopia. RECENT FINDINGS: A variety of strategies has been developed to treat amblyopia in children and adults. New evidence on the pathogenesis of amblyopia has been obtained both in animal models and in clinical trials. Mainly, these studies have challenged the classical concept that amblyopia becomes untreatable after the 'end' of the sensitive or critical period of visual development, because of a lack of sufficient plasticity in the adult brain. SUMMARY: New treatments for amblyopia in children and adults are desirable and should be encouraged. However, further studies should be completed before such therapies are widely accepted into clinical practice.
Current Opinion in Ophthalmology · 2004 · 13 citations
Amblyopia treatment studies
AbstractPURPOSE OF REVIEW: Amblyopia continues to be a major cause of vision loss in children. Several different treatment modalities exist. Research in the field of amblyopia has been very active over the past few years, and clinical practice patterns are changing. RECENT FINDINGS: Atropine has been found to be effective in the treatment of amblyopia. Less intense patching regimens have been found to be effective as well. Many other aspects of amblyopia therapy are being investigated. SUMMARY: Herein are current reviews of the major clinical amblyopia studies. Various treatment options are reviewed, and controversies in the field are discussed.
AbstractAmblyopia may be treated using specialized techniques including minimal, part-time or partial direct occlusion, red filter treatment, penalization therapy, the CAM stimulator and anti-inhibitory pharmacologic agents. Recent neurophysiological and psychophysical research has revealed much information regarding the pathogenesis and nature of amblyopia. These data provide a sound basis on which old therapeutic methods may be modified, and new treatment concepts designed. Testing techniques have been extended beyond the classic Snellen reading chart, and several subgroups of amblyopia are now recognized.
AbstractAbstract Purpose To present an update on medical treatment of amblyopia and to review recent progress in this field. Methods Various treatment modalities are reviewed, with particular emphasis to dopaminergic agents. The effect of cytycoline through various ways of administration will be discussed in detail. Results Evidence will be brought of improvement in visual function attributable to medical treatment alone or in association with part‐time occlusion. Potential adverse effects will be discussed, as well as characteristics of visual function modifications obtained. Possible guide‐lines for medical treatment of amblyopia will be offered. Conclusion It appears that medical treatment can be usefully included in the armamentarium for amblyopia therapy, particularly in difficult cases. Recently published animal experimental data on substances capable of delaying plasticity of the visual system in adults, will be hopefully transferred shortly to humans.
DOAJ (DOAJ: Directory of Open Access Journals) · 2018 · 0 citations · open access
Research progress in molecular biological mechanism of amblyopia
AbstractAmblyopia is one of the common ophthalmic diseases in children's visual development, and its pathogenesis is rather complicated. This paper summarizes the current literatures on the pathogenesis of amblyopia, and analyzes the molecular biological mechanism of visual development and amblyopia pathogenesis from the visual neurotransmitters and their receptors, cell factors, related genes and proteins, as well as the expression of regulatory kinase. In order to provide a reference for the study of visual plasticity, amblyopia pathogenesis and treatment.
Disease module: DeepOracle (Open Targets). Structures: RDKit from PubChem SMILES. Literature: retrieved by DeepSearch across 234,678,978 indexed works (targeted per-candidate search), resolved on OpenAlex.
DeCure is a research and publication project, not medical advice and not a treatment. "DeCure for X" describes a research goal, not a claim that a cure exists. Backing a cure is a contribution to fund the research — it is not an investment, and confers no yield, royalty, equity or IP ownership. Papers are published open-access by the DeCure.ai DAO.
